Skip to content

TuHURA Biosciences, Inc. HURA Financing Cash Flow

Financing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$1.56B-57.1%
CTO
Citius Oncology, Inc.CTOR
$15.13M+299%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$75.46M-24.4%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$190.75M+68,268%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$223.93M+22,903%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$1.4M

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s financing cash flow?
TuHURA Biosciences, Inc. (HURA) reported financing cash flow of $7.14M in Q1 2026.
How has TuHURA Biosciences, Inc.'s financing cash flow changed year-over-year?
TuHURA Biosciences, Inc.'s financing cash flow increased by 1403.2% year-over-year, from -$547.88K to $7.14M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.